|
U.S. FDA Grants Priority Review to Simeprevir TMC435 for Combination Treatment of Genotype 1 Chronic Hepatitis C Janssen Research & Development, Llc |
|
Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures Global Study Advances Upsher-Smith's CNS Pipeline |
|
Boehringer Ingelheim responds to FDA warning letter |
|
Svelte Drug-Eluting Stent Utilizing New Class of Bioabsorbable Drug Coating Attains 0% Clinically-Driven Events Through 12-Months in First-In-Man Study |
|
J&J's Janssen Poised to Continue Driving Growth, Outlines 10+ Potential New Product Filings by 2017 |
|
Small in Stature: New Technology from Baxter Makes an Impact |
|
GlaxoSmithKline awarded up to $200 million by U.S. government to develop new antibiotics |
|
Sandoz launches first generic version of ATACAND |
|
Pfizer Terminates Phase 3 Study of Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL) Due to Futility |
|
Forest Labs CEO Howard Solomon to retire |
|
Par Pharmaceutical Begins Shipment of Generic Atacand |
|
BD Issues 2012 Sustainability Report A Shared Value Approach |
|
CareFusion Foundation Announces Clinical Excellence Grant Recipients More than $500,000 awarded to help hospitals improve infection prevention practices |
|
Mayo Clinic Forms Joint Venture with Cancer Genetics |
|
Par Pharmaceutical Begins Shipment of Generic Atacand® |
|
Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures Global Study Advances Upsher-Smith's CNS Pipeline |
|
UPDATE: Pfizer to Split Off Remaining Interest in Zoetis |
|
BD Issues 2012 Sustainability Report A Shared Value Approach |
|
CareFusion Foundation Announces Clinical Excellence Grant Recipients More than $500,000 awarded to help hospitals improve infection prevention practices |
|
Bayer to acquire Steigerwald Arzneimittelwerk GmbH |
|
Bayer to acquire Steigerwald Arzneimittelwerk GmbH |
|
NAFDAC to Prosecute Owners of Fake Drugs' Warehouses |
|
NAFDAC to Prosecute Owners of Fake Drugs' Warehouses |
|
Actavis to Acquire Warner Chilcott to Create Premier $11 Billion Revenue Global Specialty Pharmaceutical Company - Top 3 U.S. ~$3.0 Billion Revenue Specialty Brand Business -- Expands Portfolio and Pipeline in Core Areas of Women's Health and |
|
Actavis to Acquire Warner Chilcott to Create Premier $11 Billion Revenue Global Specialty Pharmaceutical Company - Top 3 U.S. ~$3.0 Billion Revenue Specialty Brand Business -- Expands Portfolio and Pipeline in Core Areas of Women's Health and |
